FemPulse to Present Clinical Data on Vaginal Neuromodulation Ring at ICS
News related to:FemPulse GmbH · 1 min read
FemPulse, a bioelectronic medical technology company based in Vienna and San Francisco, is set to present its latest clinical data at the International Continence Society (ICS) annual meeting in Maastricht, The Netherlands, on October 9, 2026. The company's non-invasive vaginal neuromodulation Ring, which has recently received CE Mark for the EU, will be the focus of the presentation.
The FemPulse Ring is a wearable, wireless device designed to treat overactive bladder (OAB), a condition affecting one in five women worldwide. The device features eight programmable surface electrodes that target the nerves responsible for communication between the bladder and the spinal cord. According to Dr. Alexandra Haessler, the urogynecologist-developer of the FemPulse Ring, the device offers a non-invasive alternative to pharmaceutical medications.
Dr. Suzette E. Sutherland, the principal investigator of the FemPulse clinical studies, expressed enthusiasm for the upcoming presentation.
FemPulse has completed four successful clinical studies aimed at demonstrating the safety and efficacy of the device. The company will also be exhibiting the FemPulse Ring throughout the ICS conference. Thomas Huber, President of FemPulse GmbH, highlighted the company's plans to connect with clinicians and provide them with access to the quality-of-life-changing FemPulse Ring.
The FemPulse Ring is part of the company's broader mission to develop a novel wearable platform for sensing data and providing personalized treatment of medical conditions in women. The initial application of the device is to treat overactive bladder (OAB), a condition that can significantly impact a woman's quality of life. The device is CE certified for the EU but remains investigational in the United States.
FemPulse's technology represents a significant advancement in the treatment of OAB, offering a non-invasive solution that can be worn continuously. The company's focus on innovation and patient-centered care underscores its commitment to improving the lives of women suffering from this condition.